PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; ACE inhibitors; Angiotensin receptor antagonists
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PROVIDE-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Feb 2018 Planned End Date changed from 30 Jun 2018 to 17 Jun 2019.
- 28 Feb 2018 Planned primary completion date changed from 30 Jun 2018 to 17 Jun 2019.
- 28 Feb 2018 Planned initiation date changed from 31 Jan 2018 to 15 Mar 2018.